Home>Topics>>Teva files petition with U.S. FDA against MS drug competitors

Teva files petition with U.S. FDA against MS drug competitors

Reuters: Healthcare

Thu, 3 Jul 2014

TEL AVIV, July 3 (Reuters) - Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration (FDA), aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis (MS).
Content Partners